Antithrombotic prevention in vascular disease: bases for a new strategy in antithrombotic therapy

Altman, Raul
January 2007
Thrombosis Journal;2007, Vol. 5, p11
Academic Journal
A tendency toward bleeding often undercuts the beneficial preventive effect of higher doses of a single antithrombotic drug or combined antithrombotic therapy. Although high doses of antithrombotic drugs may be necessary for optimal prevention, such therapy can also elicit more frequent bleeding. Although major bleeding could be a reversible event is likely to lead clinicians to discontinue antithrombotic therapy which in turn could increase the risk of myocardial infarction, stroke, and cardiovascular death. Thus, to prevent thrombotic events without frequent bleeding complications, the preferred approach might be to use anti-inflammatory drugs in addition to the first-line antithrombotic drugs to reduce inflammation and thrombin formation in atheroma. Although some preliminary data have been already published, to confirm the potential benefit of anti-inflammatory drugs in acute coronary syndromes large prospective double-bind randomized trials are necessary.


Related Articles

  • Antithrombotic Agents for Acute Coronary Syndromes. Mukherjee, Debabrata // Cardiovascular & Hematological Agents in Medicinal Chemistry;2008, Vol. 6 Issue 2, p130 

    Current evidence suggests a central role for antithrombotic agents such as unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH) in the management of acute coronary syndromes (ACS). In patients with acute myocardial infarction, several studies have shown that LMWHs may represent an...

  • Warfarin, Aspirin, or Both after Myocardial Infarction. Hurlen, Mette; Abdelnoor, Michael; Smith, Pål; Erikssen, Jan; Arnesen, Harald // New England Journal of Medicine;9/26/2002, Vol. 347 Issue 13, p969 

    Background: The role of antithrombotic therapy in secondary prevention after myocardial infarction is well established. Although the available literature suggests that warfarin is superior to aspirin, aspirin is currently the more widely used drug. We studied the efficacy and safety of warfarin,...

  • Fondaparinux Sodium: A Review of its Use in the Management of Acute Coronary Syndromes. Blick, Stephanie K. A.; Orman, Jennifer S.; Wagstaff, Antona J.; Scott, Lesley J. // American Journal of Cardiovascular Drugs;2008, Vol. 8 Issue 2, p113 

    Fondaparinux sodium (Arixtra®) is a synthetic, sulfated pentasaccharide, selective factor Xa inhibitor that is indicated in Europe for preventing thrombus formation in patients with acute coronary syndromes (ACS; the focus of this review), including those with ST-segment elevation myocardial...

  • Spotlight on Enoxaparin in ST-Segment Elevation Myocardial Infarction. Carter, Natalie J.; McCormack, Paul L.; Plosker, Greg L. // BioDrugs;2008, Vol. 22 Issue 5, p343 

    Enoxaparin (enoxaparin sodium; Lovenox) is a low-molecular-weight heparin (LMWH) that has recently been approved by the US FDA for use in patients with medically managed ST-segment myocardial infarction (STEMI), or STEMI with subsequent percutaneous coronary intervention. It binds to and...

  • Impact of chronic oral anticoagulation on management and outcomes of patients with acute myocardial infarction: data from the RICO survey. Oudot, A.; Steg, P. G.; Danchin, N.; Dentan, G.; Zeller, M.; Sicard, P.; Buffet, P.; Laurent, Y.; Janin-Manificat, I.; L'Huillier, I.; Beer, J. C.; Makki, H.; Morel, P.; Cottin, Y. // Heart;Aug2006, Vol. 92 Issue 8, p1077 

    Objective: To determine the prevalence of chronic oral anticoagulant drug treatment (COA) among patients with acute myocardial infarction (AMI) and its impact on management and outcome. Methods: All patients with ST segment elevation AMI on the RICO (a French regional survey for AMI) database...

  • Reviparin reduced a composite endpoint of death, reinfarction, stroke, and ischemia at 7 and 30 days after acute MI. Berger, Peter B. // ACP Journal Club;Jul/Aug2005, Vol. 143 Issue 1, p11 

    This article presents a study related to effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction (MI) presenting with ST-segment elevation. Several patients were presented with suspected acute MI and ST-segment...

  • Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction. P.-G. Chassot; A. Delabays; D. R. Spahn // BJA: The British Journal of Anaesthesia;Aug2007, Vol. 99 Issue 3, p316 

    Recent clinical data show that the risk of coronary thrombosis after antiplatelet drugs withdrawal is much higher than that of surgical bleeding if they are continued. In secondary prevention, aspirin is a lifelong therapy and should never be stopped. Clopidogrel is regarded as mandatory until...

  • Acute Myocardial Infarction Caused by Delayed Heparin-Induced Thrombocytopenia and Acute Immunoreaction due to Re-exposure to Heparin in a Systemic Lupus Erythematosus Patient with HIT Antibodies. Suzuki, Shunji; Sakamoto, Susumu; Okada, Takeaki; Matsuo, Miyako; Saitoh, Atsushi; Matsuo, Takefumi // Clinical & Applied Thrombosis/Hemostasis;Oct2003, Vol. 9 Issue 4, p341 

    A patient with systemic lupus erythematosus and anti-cardiolipin antibodies and antibodies to platelet factor 4/heparin complexes suffered an acute myocardial infarction caused by delayed heparin-induced thrombocytopenia after heparin administration given to treat pulmonary hypertension....

  • Therapy for Patients with Acute Coronary Syndromes – New Opportunities. Gibbons, Raymond J.; Fuster, Valentin // New England Journal of Medicine;4/6/2006, Vol. 354 Issue 14, p1524 

    The article focuses on the authors' views on therapy for patients with acute coronary syndromes. The authors refer to the definition of acute coronary syndromes as myocardial infarction with ST-segment elevation, myocardial infarction without ST-segment elevation, and unstable angina, which...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics